Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
Related Articles
Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer
Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.
Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.
Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
Five Under 5: Top Oncology Videos for the Week of 6/8
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.
SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL
Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent…
Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS
Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.
Obe-Cel and MRD Outcomes: Insights and Comparisons
Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition…